TearScience  LipiFlow

Be proactive about your eye health and get screened. If you are diagnosed with MGD, TearScienceTM LipiFlowTM is a fast and easy in-office treatment that helps unblock the cause of MGD to get your glands functioning again. Treat the source of your dry eyes, not just the symptoms.

For patients with Meibomian Gland Dysfunction, TearScienceTM LipiFlowTM significantly improves gland secretions and ocular surface symptoms including dry eye and blurred and/or poor vision.

• TearScience™ LipiFlow™ is safe and designed to be a comfortable, FDA-cleared, in-office treatment for the inner and outer lid treatment of MGD.
• After an initial anesthetic eye drop, TearScience™ LipiFlow™ applies precise heat to the inner eyelids and gently massages the Meibomian glands to loosen the oil trapped within the glands.
• Once loosened, TearScience™ LipiFlow™ then expresses the contents while protecting the delicate structure of the eyelids.
• This treatment is designed to restore the natural oil flow to the tear film that covers the eye’s surface.
• TearScience™ LipiFlow™ is backed by data and experience, with over 700,000 treatments worldwide – and growing.

Just 1 treatment increases mean gland secretion threefold and reduces more than half of dry eye symptoms.

Do you wear contact lenses? Treatment also increased patient comfortable contact lens wear time by approximately 4 hours on average per day.

Preparing for cataract or refractive surgery? TearScience™ LipiFlow™ treatment prior to cataract surgery improves mean dry eye symptoms and vision-related function scores post-surgery.

Choose TearScience™ LipiFlow™.

Because Eye Health Starts at the Surface.

REFERENCES:

1. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31(5):472-478.
2. Willcox MDP et al. TFOS DEWS II Tear Film Report. The Ocular Surface. 2017; 15:366-403.
3. Xiao J et al. Functional and Morphological Evaluation of Meibomian Glands in the Assessment of Meibomian Gland Dysfunction Subtype and severity. Am J Ophthalmol. 2020;209:160-67.;
4. Geerling G et al. Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction – Proceedings of the OCEAN group meeting. The Ocular Surface. 2017;15:179-92;
5.  Ye F,at el. Objective assessment of tear-film quality dynamics in patients with meibomian gland dysfunction and aqueous-deficient dry eye optical quality changes in different dry eye subtypes. Indian Journal of Ophthalmology. 2019;67(5):599-603
6. Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, Lemp MA, Sullivan DA. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):1922-9. doi: 10.1167/iovs.10-6997a. PMID: 21450913; PMCID: PMC3072157.
7. Viso E, et al. Prevalence of asymptomatic and symptomatic Meibomian Gland Dysfunction in the general population of Spain. Invest Ophthalmol Vis Sci. 2012; 53(6): 2601–2606. doi: 10.1167/ iovs.11-9228.
8. Lane SS et al. A New System, the TearScienceTM LipiFlowTM, for the Treatment of Meibomian Gland Dysfunction (MGD). Cornea. 2012;31(4):396-404. For illustrative purposes only. This content is presented for educational purposes only. JJSV Surgical Vision, Inc. does not engage in the practice of medicine and any clinical tips within this content are not a substitute for appropriate medical education and training or for the exercise of independent medical judgment. Each medical situation should be considered unique to each patient and all treatments individualized accordingly based on the respective physician’s medical judgment. JJSV Surgical Vision, Inc. does not (1) warranty the accuracy or completeness of any of the clinical tips, or (2) endorse or recommend any technique.
9.  TearScienceTM LipiFlowTM IFU United States
10. Aggregate Global Sales Figures; LipiFlow at 700K treatments worldwide xlsx; Created Sep/9/2022; Data on File. Johnson & Johnson Vision Inc.
11. Blackie CA, Coleman CA, Holland EJ. The sustained effect (12 months) of a single-dose vectored thermal pulsation procedure for meibomian gland dysfunction and evaporative dry eye. Clin Ophthalmol. 2016; 10: 1385-1396.
12. Blackie CA, et al. A single vectored thermal pulsation treatment for meibomian gland dysfunction increases mean comfortable contact lens wearing time by approximately 4 hours per day. Clin Ophthalmol. 2018;12:169-183.
13. Matossian C, Chang DH, Whitman J, Clinch TE, Hu J, Ji L, Murakami D, Wang Y, Blackie CA. Preoperative Treatment of Meibomian Gland Dysfunction with a Vectored Thermal Pulsation System Prior to Extended Depth of Focus IOL Implantation. Ophthalmol Ther. 2023 Oct;12(5):2427-2439. doi: 10.1007/s40123-023-00740-x. Epub 2023 Jun 15. PMID: 37318707; PMCID: PMC10441955.